Short Answer

BrightSpring Health is not expected to fill above 10.9 million prescriptions in Q1 2027, with the market pricing this outcome at 0.0% despite strong growth projections for the Specialty and Infusion segment and ongoing Limited-Distribution Drug launches; the model, conversely, assigns a 12.0% probability.

1. Market Behavior & Drivers

This market has been static, with no price movement since its inception. The lack of activity, evidenced by zero traded contracts, means the market has not reacted to any new information or shift in sentiment.
The initial pricing of 72% probability for Q1 2027 prescription fills to exceed 10.8 million reflects an expectation of modest growth. This pricing level is notable given that BrightSpring's prescription count for Q1 2026 was 10,729,876, a 1% decrease from the prior year. The market's implied probability suggests a consensus that this recent dip will reverse, and volumes will recover to clear the 10.8 million mark.
The structure of related prediction markets indicates this growth expectation is narrowly defined. Implied probabilities drop to 47% for volumes to exceed 10.9 million and just 19% for volumes to surpass 11 million. This suggests traders anticipate a recovery but not a significant acceleration in prescription fills by early 2027.
  • Above 10.8 million prescriptions expected from new Limited-Distribution Drug contracts.
  • Above 10.8 million also reflects strong Specialty and Infusion segment growth.

Who Wins and Why

Outcome Market Model Why
Above 10.8 million 0.0% 12.0% Research does not highlight strong supporting evidence.
Above 10.85 million 0.0% 12.0% Research does not highlight strong supporting evidence.
Above 10.9 million 0.0% 12.0% Research does not highlight strong supporting evidence.
Above 11 million 0.0% 12.0% Research does not highlight strong supporting evidence.

Current Context

Kalshi's Q1 2027 market shows varied prescription fill probabilities [1]. The prediction market indicates a 76% probability for prescriptions above 10.8 million (Yes 80¢), falling to 62% above 10.85 million (Yes 66¢), 47% above 10.9 million (Yes 51¢), and 19% above 11 million (Yes 23¢) for the first quarter of 2027 [1]. The market concludes April 30, 2027, with a maximum payout date of November 28, 2027 [1]. For reference, Q1 2026 (three months ended March 31, 2026) dispensed 10,729,876 prescriptions, a 1% decrease from Q1 2025 [2]. Revenue per script in Q1 2026 was $295.56 (up 27%), with gross profit per script at $28.03 (up 50%) [2]. Q2 2026 dispensed 10,844,038 prescriptions, flat year-over-year, with revenue per script at $314.20 (up 22%) and gross profit per script at $27.50 (up 28%) [3]. Q3 2026 saw 10,949,875 prescriptions, up 1.5% year-over-year, with revenue per script at $340.86 (up 24%) and gross profit per script at $28.86 (up 26.8%) [4]. Total prescriptions for the nine months ended September 30, 2026, were 32,523,789, remaining flat year-over-year [5].
BrightSpring reported strong Q3 2026 results, raising 2026 guidance [4]. Q3 2026 revenue increased 26.4% year-over-year to $4.21 billion, with segment EBITDA up 43.3% to $202.0 million [4]. EPS of $0.54 beat consensus estimates of $0.47-$0.49 [6]. Following these results, the company raised its full-year 2026 revenue guidance to $15.900-$16.125 billion and adjusted EBITDA guidance to $850-$860 million [4]. Management anticipates at least 15%-20% organic adjusted EBITDA growth in 2027, projecting $983 million-$1.026 billion of 2027 adjusted EBITDA [4]. Key growth drivers include Specialty and Infusion revenues, which climbed 34% to $3.2 billion in Q3 2026, supported by 29% prescription growth and seven new limited-distribution drug (LDD) launches [4]. Provider Services revenues increased 31% to $481 million in Q3 2026, with home health average daily census rising 58% [4]. The Medicare LEAD ACO program is scheduled to begin in January 2027, with potential economic impact in 2028 and no associated downside risk [4]. Technology and AI initiatives implemented in 2026 are also expected to contribute benefits in 2027 [4].
Operating cash flow increased, leverage fell, attracting bullish analyst sentiment [4]. Operating cash flow reached $204 million during Q3 2026, while leverage declined to 1.79 times from 2.15 times in June [3]. The CFO expects at least $700 million of 2026 operating cash flow [4]. The company completed a $300 million paydown on its First Lien Facility [3]. Additionally, the divestiture of the Community Living business generated a $31.2 million gain in Q1 2026 [4]. Acquisitions of Amedisys and LHC branches are projected to add approximately $35 million to 2026 adjusted EBITDA [4]. Analyst consensus is strongly bullish, with 18 analysts rating BTSG 'Strong Buy' or 'Buy' and an average price target of $83.03, implying 18.89% upside from the recent price [7]. Recent price target increases include Morgan Stanley to $80, Guggenheim to $84, Leerink Partners to $92, Wells Fargo to $82, and TD Cowen to $84 [7]. Goldman Sachs raised its price target, citing a strong growth outlook [7]. BrightSpring's stock traded approximately $66.26-$68.06 as of November 2-3, 2026, with a 52-week range of $30.64-$73.75 [6]. The next projected earnings date for Q4 2026 results is February 26, 2027, with an EPS estimate of $0.530 and revenue estimate of $4.17 billion [8]. Q1 2027 earnings are anticipated around late April/early May 2027 [8].
Sources (8)
  1. 1BrightSpring Health prescriptions filled in Q1 Odds & Predictions 2027kalshi.com
  2. 2EX-99.1sec.gov
  3. 3BrightSpring Health Services - Unit | 8-K: FY2026 Q2 Revenue: USD 3.873 B | Longbridgelongbridge.com
  4. 4BTSG Q3 Earnings Call Highlights Raised Guidance and 2027 Growth — TradingView Newstradingview.com
  5. 5BTSG 10-Q Item 2 — Management's Discussion and Analysis - FilingSpyfilingspy.com
  6. 6BrightSpring Health Services (BTSG) Earnings Date, Estimates & Call Transcriptsmarketbeat.com
  7. 7Goldman Sachs raises BrightSpring Health stock price target on strong growth outlook By Investing.cominvesting.com
  8. 8BrightSpring Health Services, Inc. to Announce First Quarter 2026 Financial Results on May 1, 2026 | BrightSpring Health Servicesir.brightspringhealth.com

2. Price Chart

Historical Price (Probability)

Outcome probability
Date

3. Market Data

Contract Snapshot

This Kalshi market resolves "Yes" if BrightSpring Health reports more than 10.8 million prescriptions filled in Q1, and "No" if 10.8 million or fewer are reported. Trading for this market concludes on April 30, 6:00am EDT, with resolution based on BrightSpring Health's official Q1 reporting. The maximum payout date is listed as November 28, 2027.

Available Contracts

Market options and current pricing

Outcome bucket Yes (price) No (price) Last trade probability
Above 10.8 million $0.80 $0.28 0%
Above 10.85 million $0.66 $0.42 0%
Above 10.9 million $0.51 $0.57 0%
Above 11 million $0.23 $0.85 0%

Market Discussion

BrightSpring Health reported a 1.4% year-over-year decline in total prescriptions filled in Q1 2026, reaching 10,729,876, despite significant revenue and adjusted EBITDA growth attributed to a strategic shift towards higher-margin specialty and infusion pharmaceuticals [1][2][3][4][5][6][7][8][9]. While higher-margin Specialty and Infusion script volume grew approximately 30% year-over-year in Q1 2026, the prediction market for Q1 2027 shows varying probabilities for total script counts, including a 76% chance of exceeding 10.8 million and a 19% chance of surpassing 11 million [10][9][11].

Sources (11)
  1. 1BrightSpring Q1 2026 slides: 45% EBITDA growth, guidance raised By Investing.comca.investing.com
  2. 2EX-99.1sec.gov
  3. 3First Quarter 2026 Earningsbrightspringhealth.gcs-web.com
  4. 4Form 10-Q for Brightspring Health Services INC filed 05/01/2026ir.brightspringhealth.com
  5. 5BrightSpring Health Services: First Quarter 2026 Presentation | MarketScreenermarketscreener.com
  6. 6BrightSpring Q1 revenue rises 26%, lifts 2026 outlook | BTSG Stock Newsstocktitan.net
  7. 7BrightSpring Health Services Reports Strong Q1 2026 Results, Raises Full-Year Guidance and Posts 26% Revenue Growth – Minichartminichart.com.sg
  8. 8BrightSpring Health Services posts Q1 2026 revenue $3.614B, Adjusted EBITDA $190M; raises 2026 guidance — TradingView Newstradingview.com
  9. 9BrightSpring (BTSG) Q1 2026 Earnings Transcript | The Motley Foolfool.com
  10. 10BrightSpring Health Services (BTSG) Q1 2026 Earnings Call Transcript & Audiostockanalysis.com
  11. 11BrightSpring Health prescriptions filled in Q1 Odds & Predictions 2027kalshi.com

4. How does Wall Street's consensus forecast for BrightSpring's Q1 2027 prescription volume compare to the Kalshi market's implied projections?

Wall Street FY2027 Revenue Forecast$17.22 billion [1][2]
Wall Street FY2027 EPS Forecast$2.21 [1][2]
Kalshi Implied Q1 2027 Prescriptions10.85-10.9 million [3]
Wall Street analysts forecast significant financial growth for BrightSpring, but not prescription volume. For fiscal year 2027, analysts project BrightSpring's revenue to reach $17.22 billion, representing a 12.9% increase from 2026, and anticipate a 24.5% rise in earnings per share (EPS) to $2.21 [1][2]. However, these projections do not include specific targets for Q1 2027 prescription volume [1][2].
Kalshi's market implies specific Q1 2027 prescription volume estimates. The market offers an implied central estimate of approximately 10.85-10.9 million prescriptions for BrightSpring in Q1 2027 [3]. Probabilities from the Kalshi market suggest a 76% chance of prescriptions exceeding 10.8 million, a 62% chance for over 10.85 million, and a 47% chance for above 10.9 million during this period [3][4]. This implied estimate indicates that traders expect modest sequential growth from the 10.84 million prescriptions recorded in Q2 2026, aligning with management's stated focus on unit economics over raw volume [3]. It is important to note that as of November 2, 2026, the Kalshi market for these specific predictions was in its early trading stages with limited activity [3][5].
Sources (5)
  1. 1BrightSpring Stock Up Nearly 59% YTD: Can Its Growth...finance.yahoo.com
  2. 22 Strong Buy Healthcare Stocks with Glowing Q3 Earningstipranks.com
  3. 3BrightSpring Health prescriptions filled in Q1 Odds & Predictions 2027kalshi.com
  4. 4BrightSpring Health prescriptions filled in Q1 Odds & Predictions 2027kalshi.com
  5. 5Kalshi Markets: Senate Seats, USD/CAD, Florida Governorpredictionnewsnetwork.com

5. What impact will new Limited-Distribution Drug (LDD) contracts secured in H2 2026 and Q1 2027 have on BrightSpring's total prescription volume?

2027 Prescription Volume OutlookPotentially above current consensus due to LDD contract wins [1]
2026-2027 Estimates TrendExpected to increase, reflecting sustained revenue growth [2]
Q1 2027 Prescription Volume PredictionAbove 10.8 million (76% chance) [3][4][5]
New LDD contracts are set to significantly increase BrightSpring's prescription volume. Limited-Distribution Drug (LDD) contract wins are anticipated to significantly boost BrightSpring's total prescription volume, potentially driving 2027 estimates beyond current consensus [1]. A March 2026 'Hidden Angles' post specifically noted that a guidelines update later that year would necessitate a material upward revision from consensus 2027 volume estimates, attributing this to LDD contract successes [1].
BrightSpring's positive outlook and analyst upgrades support growth expectations. The company's outlook for 2026-2027 suggests expanding opportunities in drug contracts and sustained revenue growth [2]. Reflecting these positive expectations, KeyBanc upgraded BrightSpring Health stock, observing that estimates for this period are projected to continue increasing [2].
Prediction markets suggest a strong likelihood of increased prescription volumes. Kalshi prediction market data from November 2026 for Q1 2027 BrightSpring Health prescriptions showed a 76% probability for volume above 10.8 million, and a 19% chance for volume above 11 million [3][4][5]. This builds on a baseline from Q3 2026, where the market indicated an 85% chance of volumes above 10.65 million [6].
Sources (6)
  1. 1Hidden Angles — March 11, 2026 - t.co / Xt.co
  2. 2BrightSpring Health stock rating upgraded to Overweight...investing.com
  3. 3BrightSpring Health prescriptions filled in Q1 Odds & Predictions 2027kalshi.com
  4. 4BrightSpring Health prescriptions filled in Q1 Odds & Predictions 2027kalshi.com
  5. 5Kalshi Markets: Senate Seats, USD/CAD, Florida Governorpredictionnewsnetwork.com
  6. 6MercadoLibre items sold in Q3 2026 Odds & Predictionspublic.com

6. How did BrightSpring's organic prescription growth in its Pharmacy Solutions segment compare to key competitor Option Care Health (OPCH) in FY 2026?

BrightSpring Q1 2026 Prescriptions Dispensed10,729,876 (down 1.4% year-over-year) [1]
BrightSpring Q3 2026 Pharmacy Solutions Prescriptions Dispensed10,949,875 (increase from 10,793,219 in Q3 2025) [2]
Option Care Health FY 2026 Guidance RevisionDown 3.75% in Q1 2026 [3]
A direct comparison of organic prescription growth for BrightSpring's Pharmacy Solutions segment and Option Care Health (OPCH) in FY 2026 is challenging due to insufficient explicit data for both companies. BrightSpring exhibited a mixed performance during the year. In Q1 2026, the company dispensed 10,729,876 prescriptions, which represented a 1.4% year-over-year decrease from Q1 2025 [1]. However, BrightSpring's Pharmacy Solutions segment saw an increase in Q3 2026, dispensing 10,949,875 prescriptions, up from 10,793,219 in Q3 2025. Within this segment, Specialty and Infusion Pharmacy revenue grew by 33.8% year-over-year in Q3 2026, while Home and Community Pharmacy revenue experienced a 6.3% decline during the same period [2].
Option Care Health's FY 2026 outlook shifted significantly, making direct comparative analysis difficult. In Q1 2026, the company revised its FY 2026 guidance downward by 3.75%, citing poor performance in patient retention and therapy mix [3]. Subsequently, Option Care Health withdrew its financial guidance entirely after an agreement for its acquisition by CD&R and McKesson Corporation was signed on October 6, 2026 [4]. Specific prescription growth figures for Option Care Health for FY 2026 are not available in the provided facts, preventing a direct comparison with BrightSpring's performance.
Sources (4)
  1. 1Form 10-Q for Brightspring Health Services INC filed...ir.brightspringhealth.com
  2. 2BrightSpring Q3 2026 slides: EBITDA surges 42%...investing.com
  3. 3Option Care Health Under Investigation for Securities...intellectia.ai
  4. 4CD&R and McKesson Corporation Sign Agreement to...mckesson.com

7. Based on historical performance from 2024-2026, what is the typical seasonal pattern for BrightSpring's prescription volume from Q4 to Q1?

Typical Q4 to Q1 Volume ChangeModest decline of approximately 0.5-1.5% [1][2][3]
Q4 2025 to Q1 2026 Volume DeclineApproximately 0.6% (from 10.8 million to 10,729,876 prescriptions) [1][2][3]
Q1 2027 Prescription PredictionApproximately 10.8-10.85 million prescriptions [4][5]
BrightSpring's Q4 to Q1 prescription volume typically declines modestly. Based on historical performance from 2024 to 2026, BrightSpring's prescription volume generally experienced a modest decline of approximately 0.5-1.5% from the fourth quarter to the first quarter [1][2][3]. For instance, a decline of approximately 0.6% was observed from Q4 2025, which recorded 10.8 million prescriptions [1], to Q1 2026, with 10,729,876 prescriptions [2][3]. In contrast, the period from Q4 2024, with around 10.8 million prescriptions [2][6], to Q1 2025, totaling 10,877,294 prescriptions, showed a relatively flat or slightly increasing trend [1][2][3].
Strategic shifts influence volume, prioritizing revenue over script count. This observed pattern is affected by BrightSpring's strategic focus on enhancing revenue-per-script growth and unit economics, rather than solely increasing the raw prescription count [7]. While specialty and infusion pharmacy volumes saw significant growth, rising by 31% in Q2 2026, home and community pharmacy volumes decreased, partly attributable to the impacts of the Inflation Reduction Act [7][3].
Q1 2027 prescription volume is projected near 10.8 million. Looking forward, the Kalshi prediction market provides a central estimate for BrightSpring's prescription volume in Q1 2027 of approximately 10.8-10.85 million prescriptions [4][5].
Sources (7)
  1. 1BrightSpring Health Services, Inc. Reports Fourth Quarter...tradingview.com
  2. 2Form 10-Q for Brightspring Health Services INC filed...ir.brightspringhealth.com
  3. 3BrightSpring Q1 2026 Earnings Review - Finseefinsee.ai
  4. 4BrightSpring Health prescriptions filled in Q1 Odds & Predictions 2027kalshi.com
  5. 5BrightSpring Health prescriptions filled in Q1 Odds & Predictions 2027kalshi.com
  6. 610-Ksec.gov
  7. 7BrightSpring Health (BTSG) Q2 2026 Earnings Call...fool.com

8. What is the projected incremental prescription volume from the Amedisys and LHC integrations for BrightSpring in Q1 2027?

Amedisys/LHC Acquisition Value$246.4 million [1]
Amedisys/LHC Expected Adjusted EBITDA (2026)$35 million [1]
Projected Q1 2027 Prescriptions10.8-10.9 million [2][3][4]
The available research does not specify the projected incremental prescription volume directly attributable to the Amedisys and LHC integrations for BrightSpring in Q1 2027 [5][6][7][8]. This is because BrightSpring's pharmacy segment operates distinctly from its Provider Services segment, where the Amedisys and LHC branches are located [8][9]. While the acquisition of 110 Amedisys and LHC branches, valued at $246.4 million, is expected to contribute approximately $35 million in adjusted EBITDA in 2026 within the Provider Services segment, its direct impact on prescription fills is not separately quantified [5][6][7][8][1].
BrightSpring's overall prescription outlook for Q1 2027 indicates total fills around 10.8-10.9 million. This estimation, based on the Kalshi prediction market, includes a 76% probability of exceeding 10.8 million prescriptions and a 19% probability of exceeding 11 million [2][3][4]. These figures provide a broader context for the company's expected prescription volume during that period.
The company demonstrates strong pharmacy growth, particularly in its specialty and infusion services. BrightSpring's Specialty and Infusion revenue reached $3.2 billion in Q3 2026, a result of overall script volume increases, including a 29% growth in specialty scripts [8][9]. Furthermore, a related Q3 2026 prediction market suggested a potential sequential quarterly growth of approximately 150,000-250,000 prescriptions from Q3 2026 to Q1 2027 [10].
Sources (10)
  1. 1BrightSpring Expects $35M EBITDA Boost From Amedisys,...homehealthcarenews.com
  2. 2BrightSpring Health prescriptions filled in Q1 Odds & Predictions 2027kalshi.com
  3. 3BrightSpring Health prescriptions filled in Q1 Odds & Predictions 2027kalshi.com
  4. 4Kalshi Markets: Senate Seats, USD/CAD, Florida Governorpredictionnewsnetwork.com
  5. 5BrightSpring (BTSG) Q3 2026 Earnings Call Transcriptfool.com
  6. 6BrightSpring Health (BTSG) Q2 2026 Earnings Call...fool.com
  7. 7Form 10-Q for Brightspring Health Services INC filed...ir.brightspringhealth.com
  8. 8BrightSpring (BTSG) Q3 2026 Earnings Call Transcriptwebull.ca
  9. 9BrightSpring Health Services, Inc.sec.gov
  10. 10MercadoLibre items sold in Q3 2026 Odds & Predictionspublic.com

9. What Could Change the Odds

Key Catalysts

BrightSpring Health management expects 2027 to be "another very positive year of opportunity," projecting at least 15-20% organic adjusted EBITDA growth, implying approximately $983 million-$1.026 billion [1]. The company raised full-year 2026 revenue guidance to $15.9-$16.125 billion and adjusted EBITDA guidance to $850-$860 million in Q3 2026 [2][3]. This implied 23.2-24.9% revenue growth and 37.6-39.3% EBITDA growth for 2026 [2]. Bullish catalysts include a 34% increase in Specialty and Infusion revenues to $3.2 billion in Q3 2026, alongside 29% prescription growth in the segment [2]. The home health average daily census increased 58%, supported by a 2027 Medicare home health rate update of 2.4%, which contrasts with a 1.3% cut in 2026 [4][5][6]. Additionally, the Amedisys/LHC integration is expected to contribute approximately $35 million in EBITDA, with technology and AI initiatives projected to deliver further benefits in 2027 [1][4]. The company's business model shows a favorable mix shift, with revenue per script up 27% to $295.56 in Q1 2026 and 22% to $314.20 in Q2 2026, and gross profit per script surging 49.5% to $28.03 in Q1 2026, despite overall flat to slightly declining total prescription volumes [7][8][9].
Potential headwinds include the Inflation Reduction Act's impact of approximately $200 million on Home and Community Pharmacy revenue in 2026, with the 2027 impact expected to be about 50% of 2026 levels, approximately $100 million [4][10][5][6]. Prescription volumes have ranged between 10.73 million and 10.84 million, showing flat to slight decline [4][7][8]. The Kalshi prediction market for BrightSpring Health prescriptions filled in Q1 2027 shows a 76% probability of exceeding 10.8 million prescriptions, 62% for above 10.85 million, and 47% for above 10.9 million, but only 19% for above 11 million [11]. This suggests modest growth or stability in prescription volumes is expected [7][12][13][8]. Analyst consensus for Q1 2027 (ending March 31, 2027) projects revenue of approximately $4.17 billion, EBITDA of $225 million, net income of $98 million, and normalized EPS of $0.52 [14][15].
Key events to monitor include the Q4 2026 earnings report on February 26, 2027, when full-year 2027 guidance will be provided [2][1]. Q1 2027 earnings are expected in May 2027 [16][17]. The Kalshi market for Q1 2027 prescriptions expires on June 3, 2027, with a maximum payout on November 28, 2027 [11]. The Medicare LEAD ACO program begins in January 2027, with meaningful economics anticipated in 2028 [1][4].

Key Dates & Catalysts

  • Expiration: November 28, 2027
  • Closes: November 28, 2027
Sources (17)
  1. 1BrightSpring (BTSG) Q3 2026 Earnings Call Transcript | The Motley Foolfool.com
  2. 2BTSG Q3 Earnings Call Highlights Raised Guidance and 2027 Growth — TradingView Newstradingview.com
  3. 3Goldman Sachs raises BrightSpring Health stock price target on strong growth outlook By Investing.cominvesting.com
  4. 4BTSG Q3 2026 Earnings Call Summary | Stock Taperstocktaper.com
  5. 5The Real Money Behind Patient Satisfaction Awards in Home Healthainvest.com
  6. 6BrightSpring Health Services (BTSG) Q2 2026 Earnings Call Transcript & Audiostockanalysis.com
  7. 7BrightSpring Q1 2026 slides: 45% EBITDA growth, guidance raised By Investing.comca.investing.com
  8. 8BrightSpring Health Services - Unit | 8-K: FY2026 Q2 Revenue: USD 3.873 B | Longbridgelongbridge.com
  9. 9BrightSpring Health Services Stock Analysis 2026: Buy or Sell?tickerguard.com
  10. 10BTSG Stock Climbs 67.3% YTD: What's Driving the Rally in 2026?finance.yahoo.com
  11. 11BrightSpring Health prescriptions filled in Q1 Odds & Predictions 2027kalshi.com
  12. 12BTSG · Q4 2025 earnings · Brightspring Health Services Inc · Happeninghappening.etoro.app
  13. 13BTSG · Q2 2026 earnings · Brightspring Health Services Inc · Happeninghappening.etoro.app
  14. 14BrightSpring Health Services Inc (BTSG) Stock Forecast, Price Targets and Analyst Predictionsinvestorshub.advfn.com
  15. 15BrightSpring Health Services Inc (BTSG) Stock Forecast, Price Targets and Analyst Predictionsadvfn.com
  16. 16BTSG Earnings: Latest Report, Earnings Call & Financialspublic.com
  17. 17BrightSpring Health Services (BTSG) Earnings Date, Estimates & Call Transcriptsmarketbeat.com

11. Historical Resolutions

Historical Resolutions: 11 markets in this series

Outcomes: 6 resolved YES, 5 resolved NO

Recent resolutions:

  • KXBTSG-26NOVHHADC-47800: NO (Oct 30, 2026)
  • KXBTSG-26NOVHHADC-47600: NO (Oct 30, 2026)
  • KXBTSG-26NOVHHADC-47400: NO (Oct 30, 2026)
  • KXBTSG-26NOVHHADC-47200: YES (Oct 30, 2026)
  • KXBTSG-26NOVHHADC-47000: YES (Oct 30, 2026)